Investegate |Formycon AG Announcements | Formycon AG: Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)

Investegate announcements from Formycon AG, Formycon AG announces global license agreement with Fresenius Kabi for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)

Related Keywords

Germany ,Australia ,Japan ,United States ,Canada ,Munich ,Bayern ,Frankfurt ,Brandenburg ,America ,Johnson Stelara ,Fresenius Kabi ,Corporate Communications ,Market Scale Of The Frankfurt Stock Exchange ,Johnson ,Latin America ,Middle East ,Securities Act ,Open Market ,Frankfurt Stock Exchange ,Manager Corporate Communications ,Investegate Announcements ,Investegate Company Announcements ,Formycon Ag ,Qs ,Qs And Eqs ,